Publications by authors named "D F Bajorin"
Article Synopsis
- The IMvigor210 trial assessed the long-term efficacy and safety of atezolizumab, an anti-PD-L1 therapy, in patients with advanced metastatic urothelial carcinoma (UC), showing manageable toxicity.
- The trial involved two cohorts: untreated UC patients ineligible for cisplatin-based chemotherapy and those previously treated with platinum-based chemotherapy, with a median follow-up of up to 96.4 months.
- Results indicated objective response rates of 23.5% in untreated patients and 16.5% in previously treated patients, with median overall survival of 16.3 months and 7.9 months, respectively, along with a notable percentage of patients experiencing grade 3/4 adverse events. *
Article Synopsis
- JCO CheckMate 274 is a phase III trial comparing adjuvant nivolumab to placebo for high-risk muscle-invasive urothelial carcinoma (MIUC) post-surgery, showing improved disease-free survival (DFS) metrics with nivolumab treatment.
- The study documented results at a median follow-up of 36.1 months, with larger survival benefits noted for patients with positive PD-L1 expression.
- No new safety issues were discovered, reinforcing the role of nivolumab as standard treatment for high-risk MIUC following radical resection.
Background And Objective: Until recently, the standard first-line treatment for advanced urothelial carcinoma (UC) was platinum-based combination chemotherapy followed by avelumab maintenance therapy for patients without progressive disease (PD). For patients with advanced UC who experience PD or recurrence, standard-of-care treatment is pembrolizumab monotherapy based on the phase 3 KEYNOTE-045 study. This post hoc analysis of the KEYNOTE-045 study evaluated the efficacy of pembrolizumab compared with chemotherapy by the best response to prior platinum-based chemotherapy.
View Article and Find Full Text PDFPurpose: Paclitaxel, ifosfamide, and cisplatin (TIP) is an established salvage regimen for germ cell tumors (GCT) on the basis of a phase II trial, but efficacy on a large patient cohort including patients with unfavorable risk features and long-term outcomes has not been reported. Herein, we report updated treatment efficacy and long-term follow-up with TIP.
Patients And Methods: Patients with GCT who received TIP after cisplatin-based chemotherapy were eligible.
Small cell carcinomas (SMC) of the lung are now molecularly classified based on the expression of transcriptional regulators (NEUROD1, ASCL1, POU2F3, and YAP1) and DLL3, which has emerged as an investigational therapeutic target. PLCG2 has been shown to identify a distinct subpopulation of lung SMC with stem cell-like and prometastasis features and poor prognosis. We analyzed the expression of these novel neuroendocrine markers and their association with traditional neuroendocrine markers and patient outcomes in a cohort of bladder neuroendocrine carcinoma (NEC) consisting of 103 SMC and 19 large cell NEC (LCNEC) assembled in tissue microarrays.
View Article and Find Full Text PDF